FGFR4 and hepatocellular carcinoma: Gao and co-workers demonstrated that FGF19/FGFR4 signaling in hepatocellular carcinoma (HCC) cells is one of the main resistance mechanisms to sorafenib, a multikinase inhibitor inducing the ROS (reactive oxygen species)-associated apoptosis [39].